We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral-experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.
with the previously administered drugs, plus ribavirin for 12-24 weeks (24 weeks in patients with an F3 or F4 METAVIR fibrosis score) [1] . We report a prospective, open-label, "realworld" study performed to evaluate the efficacy and safety of sofosbuvir, daclatasvir, and simeprevir with ribavirin in chronically infected patients whose prior treatment failed.
METHODS

Patients and Treatment
The study included 10 consecutive patients who had previously experienced relapse after treatment with an all-oral DAA-based combination regimen administered for 12 weeks without ribavirin; all were also enrolled in the ANRS CO22 HEPATHER cohort [6] and in the French National Observatory for HCV Resistance to Antiviral Drugs, and all provided written informed consent. The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the ethics committee Ile de France III. Patients were treated for 24 weeks with a combination of sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weightbased ribavirin dosage (1000-1200 mg/d).
Assessments
Safety and tolerability were assessed monthly and included regular physical examinations, adverse event assessment, and clinical laboratory blood sample testing. HCV RNA levels were measured using the Abbott RealTime HCV assay (Abbott Molecular) with identical lower limits of quantification and detection of 12 IU/mL (1.1 log IU/mL). Antiviral efficacy was assessed by measuring HCV RNA levels at baseline; at weeks 4, 8, 12, 16, 20 , and 24 (end of treatment); and at 4 and 12 weeks after treatment. The main efficacy end points were the on-treatment virological responses (HCV RNA <12 IU/mL) and SVR (HCV RNA <12 IU/mL) 12 weeks after the end of treatment (SVR12) [11] .
The presence of resistance-associated substitutions was assessed in all patients before retreatment (retreatment baseline) and after treatment in those in whom SVR12 was not achieved, as well as in any patient discontinuing treatment prematurely. HCV resistance analysis was based on population sequencing of the regions coding for the NS3/4A protease (targeted by simeprevir), the NS5A protein (targeted by daclatasvir), and the NS5B polymerase (targeted by sofosbuvir), as described elsewhere [12] .
Statistical Analyses
Descriptive results are presented as means with standard deviations or medians with interquartile ranges for continuous data, and as numbers (with percentages) for categorical data. No formal statistical analyses were undertaken.
RESULTS
Patients
Eight of the 10 re-treated patients completed treatment. The median interval between the end of prior DAA treatment and initiation of retreatment was 14 months (range, 5-28 months). Baseline characteristics are detailed in Table 1 .
Safety and Tolerability
Two patients of 6 with compensated (Child-Pugh A) cirrhosis discontinued treatment prematurely owing to serious adverse events (SAEs). Pulmonary arterial hypertension (PAH) was revealed by severe dyspnea at treatment week 6 in a patient (FibroScan value, 42 kPa; Child-Pugh score; A5, platelet count, 58 × 10 3 /µL) previously treated with 4 different antiviral regimens. Liver test results and renal function were normal, and the mean pulmonary arterial pressure was 54 mm Hg (rightsided heart catheterization). Symptoms improved after DAA discontinuation and treatment of PAH with bosentan and sildenafil [13] . Acute-on-chronic liver failure, ascribed to mitochondrial toxicity, occurred in a patient (FibroScan value, 34 kPa; ChildPugh score, A6; platelet count, 67 × 10 3 /µL) with a history of esophageal variceal bleeding 6 years before retreatment, without acute decompensation. This patient had no comorbid conditions. He had been previously treated with 3 different antiviral regimens. Jaundice developed at treatment week 4 without other symptoms. A further increase in the serum conjugated bilirubin level (up to 169 µmol/L) associated with pruritus and asthenia led to treatment discontinuation and hospitalization. Within a few days the alanine aminotransferase level increased moderately, and prothrombin time decreased to subnormal levels. The clinical course was characterized by the development of ascites, grade 1 renal failure, and acute pancreatitis. There was a parallel steady increase in serum conjugated bilirubin level, associated with mild elevation in alanine aminotransferase levels (1.5 times the upper limit of normal), and the prothrombin time remained subnormal. Markers of mitochondrial toxicity were transiently detectable, including elevation in creatine phosphokinase activity (3 times the upper limit of normal) and blood lactate level (4 mmol/L). Grade 2 acute-on-chronic liver failure subsequently developed, with acute renal failure unresponsive to terlipressin, followed by spontaneous bacterial peritonitis 2 weeks after treatment discontinuation and death from severe sepsis.
Efficacy
On-treatment virological response was achieved in all patients (HCV RNA <12 IU/mL), and SVR12 in 6 patients ( Table 2) .
Those in whom SVR12 was not achieved included 2 patients, both with HCV genotype 1a and cirrhosis, who experienced relapse after treatment, and the 2 patients with SAEs. The resistance profiles at retreatment baseline and after treatment in this study are detailed in Table 2 .
DISCUSSION
In patients with HCV genotype 1 or 4 and those with F3 fibrosis or compensated cirrhosis, in whom treatment with an NS5A inhibitor has failed, EASL recommends retreatment with ribavirin plus either sofosbuvir, grazoprevir, and elbasvir or sofosbuvir, simeprevir, and daclatasvir for 24 weeks [1] . Sofosbuvir, simeprevir, and daclatasvir were the only HCV DAAs available as single agents at the time of the study. This combination with or without ribavirin has therefore been widely used off label to re-treat patients with advanced fibrosis or cirrhosis in whom SVR was not achieved. Thus, we evaluated this combination in patients requiring retreatment. Only the IMPACT study has evaluated a ribavirin-free version of the same regimen administered for 12 weeks in 40 treatment-naive or treatment-experienced patients with decompensated cirrhosis or portal hypertension. No discontinuation due to adverse events occurred, and a 100% SVR12 rate was achieved [14] , compared with a 60% SVR12 rate and discontinuation due to SAEs by 2 patients in our study. The between-study differences can probably be explained by the fact that our patients had more advanced liver disease and had already experience a failed DAA-based regimen.
Both patients with SAEs discontinuing treatment in our study had advanced liver disease, low platelet counts, and portal hypertension. However, neither had a history of decompensation, and they did not have any indications for liver transplantation. There have been reports of severe PAH in patients receiving interferon therapy [15] and in those receiving sofosbuvir-containing therapy, suggesting that this SAE could be related to either the patients' current or past treatment [13, 16] .
In contrast, mitochondrial toxicity has not been reported with DAAs, although asymptomatic increases in lipase activity and lactic acidosis and 2 cases of self-limited pancreatitis have been reported with sofosbuvir and simeprevir and with sofosbuvir and ribavirin [17] [18] [19] [20] , indicating that the severe episode of mitochondrial toxicity observed in our study could be treatment related. In addition, although the condition was diagnosed as mitochondrial toxicity at the time, we could not rule out protease inhibitor-induced hepatotoxicity.
The 2 patients who experienced relapse were infected with HCV genotype 1a, had cirrhosis (FibroScan values, 15 and 22 kPa), and harbored NS5A and/or NS3 protease resistance-associated substitutions at baseline, which are known to confer reduced susceptibility to daclatasvir and simeprevir, respectively [10, [21] [22] [23] [24] [25] [26] [27] [28] [29] . As expected, NS5A and NS3 protease resistance-associated substitutions were present after therapy in both patients. However, EASL does not recommend routine resistance testing before first-line treatment initiation, owing to unreliable access and no consensus on techniques. However, resistance testing is useful in patients exposed to NS5A inhibitors [1] . Therefore, clinicians should assess the likelihood of treatment failure based on other risk factors, for example, advanced liver disease (irrespective of HCV genotype or treatment regimen), HCV genotype 1, cirrhosis, and low platelet count (suggestive of advanced liver disease with portal hypertension) [5, 10] . These 2 patients represent a subpopulation that is particularly difficult to re-treat, which emphasizes the need for optimizing first-line treatment of HCV, as recently recommended, to minimize treatment failure, selection of resistant viruses, and the subsequent need for rescue therapy [8] .
To our knowledge, the current study provides the first report on the safety and efficacy of retreatment with sofosbuvir, daclatasvir, simeprevir, and ribavirin for 24 weeks in HCV-infected patients. In conclusion, the findings of our open-label, real-life study indicate that this combination is initially efficacious in a heterogeneous population with compensated liver disease in whom prior DAA treatment had failed. However, relapses and SAEs had a major impact on the SVR rate. Thus, we suggest that this combination be used with extreme caution in patients with compensated cirrhosis. Other options should be available in the future for retreatment of patients in whom DAA-containing regimens fail.
